Thursday, July 31, 2014

CHMP Has More Issues with Weight Loss Drug

Orexigen Therapeutics Inc. announced it has received the Day 180 List of Outstanding Issues (LOI) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the NB32 Marketing Authorization Application (MAA).






via Get Fit Bookmark http://ift.tt/1qO1opH

via Tumblr http://ift.tt/1oShvQ6

No comments:

Post a Comment